# US 2016/0355785 A1 · Expansion of adult stem cells in vitro

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355785 A1
- Document ID: US20160355785A1
- Status: Published application
- Kind: A1
- Application number: 15/179,735
- Filed: 2016-06-10
- Published: 2016-12-08
- Earliest claimed: 2013-03-11
- Assignees: Taiga Biotechnologies, Inc.
- Applicants: Taiga Biotechnologies, Inc.
- Inventors: Brian Curtis TURNER; Yosef REFAELI; Gregory BIRD
- Web page: https://patentgrep.com/patent/US20160355785A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C07K 14/4747: {Apoptosis related proteins}
- C07K 14/82: Translation products from oncogenes
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 2319/00: Fusion polypeptide
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/48: Regulators of apoptosis
- C12N 2501/606: c-Myc
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2510/04: Immortalised cells
- C12N 2740/15033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.

## Claims

### Claim at position 1

-58. (canceled)

### Claim 59

A method for producing a population of conditionally immortalized adult stem cells comprising:
a) contacting one or more adult stem cells with
i) an exogenously synthesized Myc-fusion polypeptide that promotes one or more of cell survival or proliferation, wherein the Myc-fusion polypeptide comprises a Myc polypeptide fused to a protein transduction domain; and
ii) an exogenously synthesized Bcl-2 domain polypeptide that inhibits apoptosis; and
b) seeding the adult stem cells in a culture vessel so as to produce a population of conditionally immortalized adult stem cells,
wherein adult stem cells are contacted with the Myc-fusion polypeptide and the Bcl-2 domain polypeptide prior to seeding and wherein the Myc-fusion polypeptide and the Bcl-2 domain polypeptide are cultured with the cells in the culture vessel for at least 24 hours.

### Claim 60 (depends on 59)

The method of claim 59, wherein the Myc-fusion polypeptide is provided at intervals at least 72 hours; and the Bcl-2 domain polypeptide is at intervals of at least 72 hours.

### Claim 61 (depends on 59)

The method of claim 59, wherein the Myc polypeptide of the Myc-fusion polypeptide is one or more of n-Myc, c-Myc, 1-Myc, v-Myc, or s-Myc.

### Claim 62 (depends on 59)

The method of claim 59, wherein the Myc-fusion polypeptide is provided at a concentration of about 1 ug/ml to about 50 ug/ml.

### Claim 63 (depends on 59)

The method of claim 59, wherein the Bcl-2 domain polypeptide is provided at a concentration of about 1 ug/ml to about 50 ug/ml.

### Claim 64 (depends on 59)

The method of claim 59, wherein the Bcl-2 domain polypeptide includes BH1, BH2, BH3, and BH4.

### Claim 65 (depends on 59)

The method of claim 59, wherein the one or more Bcl-2 domain polypeptide is one or more of Bcl-2, Bcl-w, Bcl-X, Bel-XL, Mcl-1.

### Claim 66 (depends on 59)

The method of claim 59, wherein the one or more Bcl-2 domain polypeptide is Bcl-2.

### Claim 67 (depends on 59)

The method of claim 59, wherein the Bcl-2 polypeptide includes a protein transduction domain selected from the group consisting of Tat, EPTD and vpr.

### Claim 68 (depends on 67)

The method of claim 67, wherein the protein transduction domain is Tat.

### Claim 69 (depends on 67)

The method of claim 67, wherein the protein transduction domain is EPTD.

### Claim 70 (depends on 67)

The method of claim 67, wherein the protein transduction domain is vpr.

### Claim 71 (depends on 59)

The method of claim 59, wherein the one or more adult stem cells are cultured in media comprising IL3, IL6, and stem cell factor.

### Claim 72 (depends on 59)

The method of claim 59, wherein the one or more adult stem cells are cultured in media comprising IL3, IL6, stem cell factor, thrombopoeitin, and Flt3-L, and GM-CSF.

### Claim 73 (depends on 59)

The method of claim 59, wherein the one or more adult stem cells are expanded one or more of about 270 fold over about 28 days, about 150 fold over about 14 days, 100 fold over about 21 days, or about 85 fold over about 9 to 14 days.

### Claim 74 (depends on 59)

The method of claim 59, wherein the one or more adult stem cells are one or more hematopoietic adult stem cells.

### Claim 75 (depends on 74)

The method of claim 74, wherein the hematopoietic adult stem cells are human cord blood-derived hematopoietic stem cells, human G-CSF mobilized peripheral blood hematopoietic stem cells, or human bone marrow hematopoietic stem cells.

### Claim 76 (depends on 59)

The method of claim 59, wherein, over a 8 hour period, no more than 1 μg/ml of Myc-fusion polypeptide is provided.

### Claim 77 (depends on 59)

The method of claim 59, wherein the Myc-fusion polypeptide is provided at intervals at least 96 hours; and the Bcl-2 domain polypeptide is at intervals of at least 96 hours.

### Claim 78 (depends on 59)

The method of claim 59, wherein the Myc-fusion polypeptide is provided at intervals at least 48 hours; and the Bcl-2 domain polypeptide is at intervals of at least 48 hours.
